Who
Steven L. Basta
President and CEO
Company insider
Files Form 4 as: President and CEO, Phathom Pharmaceuticals; Chief Executive Officer, VYNE Therapeutics; Director, Viveve Medical; Director, KalVista Pharmaceuticals; Chief Executive Officer, Bioform Medical.
In numbers
- Trades disclosed
- 77
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $82K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 9 Jul 2008
- Last trade
- 10 Feb 2026
- Last filed
- 12 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,362 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $80K6,277 at $12.82 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,362 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $80K6,277 at $12.82 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —251,034 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,156 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —226,156 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —251,034 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —62,038 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $484K31,502 at $15.36 | filing |
| 12 Dec 2025filed 15 Dec 2025 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —90,000 at $0.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —90,000 at $0.00 | filing |
| 28 Nov 2025filed 2 Dec 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $756K48,375 at $15.62 | filing |
| 25 Sep 2025filed 26 Sep 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —90,000 at $0.00 | filing |
| 25 Sep 2025filed 26 Sep 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —90,000 at $0.00 | filing |
| 25 Sep 2025filed 26 Sep 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $564K48,375 at $11.66 | filing |
| 3 Apr 2025filed 3 Apr 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 3 Apr 2025filed 3 Apr 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,085,000 at $0.00 | filing |
| 12 Dec 2024filed 13 Dec 2024 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.